



United States Pharmacopeia
The Standard of QualitySM

December 19, 2003

Jeffrey R. Bernstein, Ph.D.
Vice President, Chief Financial Officer
Winston Laboratories, Inc.
100 Fairway Drive, Suite 134
Vernon Hills, IL 60061

Sophia V. Fuerst
Director, USAN Program and Secretary, USAN Council
American Medical Association
515 North State Street
Chicago, IL 60610

Dear Dr. Bernstein and Ms. Fuerst:

I am writing to you in my capacity as Secretary of the USAN Review Board. The USAN Review Board determination was to deny Winston Laboratories' Petition to the USAN Review Board, dated March 17, 2003, thus upholding the decision of the USAN Council.

Pursuant to Section 23 of the Rules of Procedure of the USAN Review Board, the following vote of each Board member was recorded:

Donald R. Bennett, M.D., Ph.D., opposed
Jordan L. Cohen, Ph.D., opposed
Stuart Feldman, Ph.D., opposed
Lauren A. Woods, M.D., Ph.D., opposed
Gary L. Yingling, J.D., M.S., opposed
Alice Jean Matuszak, Ph.D., recused herself from discussion and decision in this matter

Pursuant to Section 1 of the Rules, this decision is final. The decision will be reported to the American Medical Association, the United States Pharmacopeial Convention, and the American Pharmaceutical Association, as further required by the Rules.

Very truly yours,

Joseph G. Valentino
Secretary, USAN Review Board

cc: USAN Review Board
Michael D. Maves, M.D., American Medical Association
Roger L. Williams, M.D., United States Pharmacopeial Convention
John A. Gans, PharmD., American Pharmaceutical Association

Winbrook Parkway
Rockville, MD 20852

301-881-0666

www.usp.org